|
Exfoliation Syndrome
|
0.310 |
Biomarker
|
disease |
BEFREE |
Long suspected to be a genetic disorder on the basis of familial aggregation studies, recent genome-wide association studies uncovered strong association between 7 genetic loci (LOXL1, CACNA1A, FLT1-POMP, TMEM136-ARHGEF12, AGPAT1, RBMS3, and SEMA6A) and increased risk of XFS.
|
29965897 |
2018 |
|
Exfoliation Syndrome
|
0.310 |
Biomarker
|
disease |
CTD_human |
Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci.
|
28553957 |
2017 |
|
Carcinoma of lung
|
0.150 |
GeneticVariation
|
disease |
GWASCAT |
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.
|
28604730 |
2017 |
|
Carcinoma of lung
|
0.150 |
Biomarker
|
disease |
BEFREE |
Expression of the RNA-binding protein HnRNP-L was previously shown to associate with tumorigenesis in liver and lung cancer.
|
28038443 |
2017 |
|
Carcinoma of lung
|
0.150 |
Biomarker
|
disease |
BEFREE |
We selected seven genes (CRP, GPC5, ACTA2, AGPHD1, SEC14L5, RBMS3, and GKN1) that previously reported link to lung cancer (LC) and genotyped single nucleotide polymorphisms (SNPs) of these genes in a case-control study.
|
25999661 |
2015 |
|
Carcinoma of lung
|
0.150 |
Biomarker
|
disease |
BEFREE |
Here we identify the RNA-binding protein QKI as a key regulator of alternative splicing in lung cancer.
|
24722255 |
2014 |
|
Carcinoma of lung
|
0.150 |
Biomarker
|
disease |
BEFREE |
alpha CP-4 is an RNA-binding protein coded by PCBP4, a gene mapped to 3p21, a common deleted region in lung cancer.
|
15205328 |
2004 |
|
Carcinoma of lung
|
0.150 |
GeneticVariation
|
disease |
BEFREE |
L523S, an RNA-binding protein as a potential therapeutic target for lung cancer.
|
12644826 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.110 |
Biomarker
|
disease |
BEFREE |
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.
|
30799057 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the gene encoding the RNA-binding protein TDP-43 cause amyotrophic lateral sclerosis (ALS), clinically and pathologically indistinguishable from the majority of 'sporadic' cases of ALS, establishing altered TDP-43 function and distribution as a primary mechanism of neurodegeneration.
|
30290270 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
|
30266754 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.
|
30804561 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The RNA binding protein 3 (RBMS3) acts as a tumor suppressor in various cancers.
|
30819235 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human embryonic lethal abnormal visual-like protein, HuR, belongs to a member of the Hu family of RNA-binding protein and plays a critical role in urinary tumors.
|
30370480 |
2019 |
|
Aspartate aminotransferase measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Biomarker and Genomic Risk Factors for Liver Function Test Abnormality in Hazardous Drinkers.
|
30589442 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We found that the expression levels of the hub genes CDC45, CDCA5, GINS2, RAD51 and TROAP in the turquoise module increased gradually during tumorigenesis, whereas those of MAGI2-AS3 and RBMS3 in the green module decreased during tumorigenesis.
|
30887286 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
|
30266754 |
2019 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TDP-43 is an RNA-binding protein active in splicing that concentrates into membraneless ribonucleoprotein granules and forms aggregates in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
|
29438978 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in <i>Matrin 3</i> (<i>MATR3</i>), a poorly understood DNA- and RNA-binding protein, cause familial ALS/FTD, and MATR3 pathology is a feature of sporadic disease, suggesting that MATR3 dysfunction is integrally linked to ALS pathogenesis.
|
30015619 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA‑binding protein‑mediated post‑transcriptional regulation is important in the initiation and development of cancer.
|
29658587 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, luciferase reporter assays and RNA-binding protein immunoprecipitation assays suggest that this is due to MEX3B binding to the 3' untranslated region (UTR) of <i>HLA-A</i> to destabilize the mRNA.<b>Conclusions:</b> MEX3B mediates resistance to cancer immunotherapy by binding to the 3' UTR of <i>HLA-A</i> to destabilize the <i>HLA-A</i> mRNA and thus downregulate HLA-A expression on the surface of tumor cells, thereby making the tumor cells unable to be recognized and killed by T cells.<i>Clin Cancer Res; 24(14); 3366-76.
|
29496759 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The RNA-Binding Protein PCBP1 Functions as a Tumor Suppressor in Prostate Cancer by Inhibiting Mitogen Activated Protein Kinase 1.
|
30078000 |
2018 |